Message Font: Serif | Sans-Serif
 
UnThreaded | Threaded | Whole Thread (2) | Ignore Thread Prev | Next
Author: Adenovir Big red star, 1000 posts Old School Fool Add to my Favorite Fools Ignore this person (you won't see their posts anymore) Number: of 48  
Subject: Re: DNAPrint Genomics Date: 10/29/2001 1:26 PM
Post New | Post Reply | Reply Later | Create Poll . Report this Post | Recommend it!
Recommendations: 0
DNAPrint Genomics 'Solves' Human Eye Color and Announces the Development of First Commercial Product.


SARASOTA, Fla., Oct 29, 2001 /PRNewswire via COMTEX/ -- DNAPrint genomics, Inc.
(OTC Bulletin Board: DNAP) announced today that its scientists ha (RETINOME(SM)
is capable of using a DNA specimen to predict the degree to which an
individual's retinas are pigmented with over 96% accuracy. Until now, forensic
DNA testing has only been able to produce "bar- code like" data from DNA, which
is limited in utility for matching a DNA specimen with another previously
derived from the same donor. If not matched to another previously obtained
result, current tests are of limited use because they reveal no qualitative
information about the donor (such as eye color, hair color, skin shade, weight
or height). DNAPrint believes its new RETINOME(SM) product is the first
comprehensive genetic test capable of revealing qualitative trait information
from human DNA. As a new forensics tool, RETINOME(SM) could help law enforcement
target investigations and provide probable cause for requesting a standard DNA
test from criminal suspects. As a research tool, RETINOME(SM) could accelerate
drug development for pigmentation related diseases such as cataracts and
melanoma.

DNAPrint has filed a U.S. patent application (US patent pending serial NO.
60/300,187) covering the composition of matter and methods related to the
RETINOME(SM) discovery. The company has also submitted a manuscript describing
the "solution" to a major scientific journal. The solution incorporates compound
genotypes from five haplotype systems in four different genes. The four genes
were previously known from genetics of human diseases (such as oculocutaneous
albinism) to be involved in the synthesis of the main pigment (eumelanin)
responsible for the coloration of human tissues. However, two of the four genes
were not previously known to be specifically involved in retinal pigmentation.
DNAPrint scientists first discovered numerous SNPs in a number of candidate
genes using proprietary discovery protocols and software. Haplotypes
incorporating a subset of these SNPs, in a subset of these genes, were then
assembled and linked to various eye color shades with a high degree of
statistical certainty (average p[haplotype system at the population level]=
0.007). The company then applied proprietary and third-party computational
methods to assemble these haplotypes into a classification "solution" of
compound genotypes that explained most of the variation in natural eye color
shade in the project study group (n=276). Previous attempts to "solve" variable
eye color by others had been hampered by the inter- and intra-genic complexity
of the trait. DNAPrint was able to overcome these challenges using its
innovative complex genetics informatics platform with a variety of algorithmic
methods for identifying genetic features, detecting genetic pattern and
constructing classification trees.

"Had we performed this work like others, on simple genetics terms, we would
never have found the answer," said Dr. Tony Frudakis, Ph.D., CEO and CSO of
DNAPrint genomics, Inc. "It is because of our blend of computational, genetics
and mathematical expertise that we are able to tease the complex genetics of eye
color from the data, and it is because of this expertise that RETINOME(SM) is
possible."

The SNPs that the company used to construct the solution represent a small
component of the company's developing PHENOME(SM) database of proprietary SNPs,
which covers most of the genes involved in variable drug reactivity. "The
RETINOME(SM) solution reflects positively on the company's informatics
capabilities, the quality of its data production and its ability to manage
complex genomics datasets. "Our timely success with the RETINOME(SM) project
validates our data resources and analytical prowess as a real and present force
for pharmacogenomics research and product development," said Venkateswarlu
Kondragunta, Vice-President of DNAPrint genomics, Inc.

RETINOME(SM) complements (rather than replaces) current DNA testing in the
multi-million dollar forensics DNA testing market. The market for pigment
related disease treatments could exceed $100 Million annually. The company will
now proceed to identify a licensee for the RETINOME(SM) technology in order to
effect its rapid commercialization. RETINOME(SM) is the company's first
genomics-based classification product, and it joins only a handful of complex
genetics predictive tools. After its licensing and validation by a
commercialization partner, RETINOME(SM) is expected to provide DNAPrint's first
substantial source of product-derived revenue.

About DNAPrint genomics, Inc.:

DNAPrint genomics Inc. was founded by a team of scientists with research and
commercial experience in high-level mathematical modeling, programming and
molecular genetics. The Company is traded on the NASDAQ OTC Bulletin Board under
the ticker symbol -- DNAP. For more information about the company, please visit
http://www.dnaprint.com/.

All statements in this press release that are not historical are forward-
looking statements within the meaning of Section 21E of the Securities Exchange
Act as amended. Such statements are subject to risks and uncertainties that
could cause actual results to differ materially from those projected, including,
but not limited to, uncertainties relating to technologies, product development,
manufacturing, market acceptance, cost and pricing of DNAPrint's products,
dependence on collaborations and partners, regulatory approvals, competition,
intellectual property of others, and patent protection and litigation. DNAPrint
genomics, Inc. expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements contained
herein to reflect any change in DNAPrint's expectations with regard thereto or
any change in events, conditions, or circumstances on which any such statements
are based.


 Inquiries please contact:
 Tim Wilkins, 941/341-0136
 Or
 Carrie Castillo, 941/366-3400


 MAKE YOUR OPINION COUNT - Click Here
 http://tbutton.prnewswire.com/prn/11690X44344435

SOURCE DNAPrint genomics, Inc.


CONTACT: Tim Wilkins, +1-941-341-0136, or Carrie Castillo,
 +1-941-366-3400, both of DNAPrint genomics, Inc.

URL: http://www.dnaprint.com
http://www.prnewswire.com

Copyright (C) 2001 PR Newswire. All rights reserved.



KEYWORD: Florida
INDUSTRY KEYWORD: MTC
 BIO
SUBJECT CODE: PDT


Post New | Post Reply | Reply Later | Create Poll . Report this Post | Recommend it!
Print the post  
UnThreaded | Threaded | Whole Thread (2) | Ignore Thread Prev | Next

Announcements

Post of the Day:
Value Hounds

Kate Spade's Wild Ride
What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Community Home
Speak Your Mind, Start Your Blog, Rate Your Stocks

Community Team Fools - who are those TMF's?
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and "#1 Media Company to Work For" (BusinessInsider 2011)! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.
Advertisement